Internationale Partnersuche

Innovation & Technologie Angebot

Resarch group offers in-vitro test systems for the detection of organotoxicity

Country of Origin: Germany
Reference Number: TODE20161011001
Publication Date: 11 October 2016

Summary

A research and development (R&D) group from the Northeast of Germany offers cell based in-vitro test systems for pharmaceutical and chemical industry as well as basic research. In vitro-tests systems are established for investigation of hepatocity, neurotoxicity and leucocyte immunoparalysis. The research group is seeking for partner for joint research and innovation projects or technical cooperation. Furthermore licensing of technologies is possible.

Description

A research and development (R&D) group from the Northeastern part of Germany offers a wide range of analytical and diagnostic methods. Cell-based biosensors are used for early detection of organ failure and assessment of prognosis in critically ill patients: Liver, nervous system and immune system.



Organ failure is associated with a high mortality and can be caused by acute diseases or medication. Organ damage caused by medication is the most common reason for withdrawing drugs that have already been approved for the market. 



However, there is no reliable test system available at present to detect organ failure at an early stage. This gave rise to the development of a microtiter plate assay based on human cells that can be used to detect organ failure at an early stage in a clinical setting and to evaluate the toxicity of drugs and medical devices. By optimizing and standardizing the procedure, reliable statements can be made with regard to exogenous and endogenous toxicity. 



In-vitro test systems are implemented to replace, reduce and refine (3R principle) animal trails. The assays are useable for pharmaceutical (toxicology, drug development, efficacy testing, bioactivity assays, quality control) and chemical industry (toxicity testing) as well as basic research. 



The following in-vitro test systems are established for investigation of hepatotoxicity, neurotoxicity and leukocyte immunoparalysis.



All tests are performed according to DIN EN ISO/IEC 17025:2005-08 to ensure a high accuracy of results.



The R&D group looks for partners for joint research and innovation projects or technical cooperation. Licensing of technologies is also possible. 



Partners could be companies that want to test (in-vitro) their products with regard to hepatotoxicity, neurotoxicity and leukocyt immunoparalysis.  Also research institutions that want to cooperate within Horizon 2002 or other R&D projects could become a partner. License agreements, research or technical cooperation agreements are possible.

Advantages and Innovations

The cell-based test systems can be used to replace, reduce and refine (3R principle) animal trails. The assays are useable for pharmaceutical (toxicology, drug development, efficacy testing bioactivity assays, quality control) and chemical industry (toxicity testing) as well as basic research.

Stage Of Development

Already on the market

Stage Of Development Comment

The in-vitro test systems are completely implemented in the lab. We perform all tests according to DIN EN ISO/IEC 17025:2005-08 to ensure a high accuracy of results.

Requested partner

The preferred partnership is with companies that want to test (in-vitro) their products with regard to hepatotoxicity, neurotoxicity and leukocyte immunoparalysis. 



Also a cooperation with research institutions within H2020 and other R&D projects is possible.